263 related articles for article (PubMed ID: 35802461)
1. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Little JS; Aleissa MM; Beluch K; Gonzalez-Bocco IH; Marty FM; Manne-Goehler J; Koo S; Hammond SP; Jacobson CA
Blood Adv; 2022 Aug; 6(16):4821-4830. PubMed ID: 35802461
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.
Pennese E; Salutari P; Carriero L; Restuccia F; De Filippis AF; De Luca G; Giancola R; Guardalupi F; Corradi G; Fabi B; Baldoni S; Di Ianni M
Front Immunol; 2023; 14():1272798. PubMed ID: 37841271
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
5. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
7. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
8. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
Haidar G; Garner W; Hill JA
Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
10. Invasive Fungal Disease Among Pediatric and Adolescent Patients Undergoing Itraconazole Prophylaxis After Hematopoietic Stem Cell Transplantation.
Itsaradisaikul S; Pakakasama S; Boonsathorn S; Techasaensiri C; Rattanasiri S; Apiwattanakul N
Transplant Proc; 2021; 53(6):2021-2028. PubMed ID: 33994183
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
12. Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Enger K; Tonnar X; Kotter E; Bertz H
Ann Hematol; 2023 Feb; 102(2):413-420. PubMed ID: 36460795
[TBL] [Abstract][Full Text] [Related]
13. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
Wang J; Alkrekshi A; Dasari S; Lin HC; Elantably D; Armashi ARA
Bone Marrow Transplant; 2023 Nov; 58(11):1223-1228. PubMed ID: 37604871
[TBL] [Abstract][Full Text] [Related]
14. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center.
Lum L; Lee A; Vu M; Strasser S; Davis R
Transpl Infect Dis; 2020 Dec; 22(6):e13361. PubMed ID: 32510755
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis.
Czyżewski K; Gałązka P; Frączkiewicz J; Salamonowicz M; Szmydki-Baran A; Zając-Spychała O; Gryniewicz-Kwiatkowska O; Zalas-Więcek P; Chełmecka-Wiktorczyk L; Irga-Jaworska N; Bień E; Ociepa T; Wawryków P; Tomaszewska R; Płonowski M; Pierlejewski F; Gamrot-Pyka Z; Małas Z; Urbanek-Dądela A; Stolpa W; Zaucha-Prażmo A; Goździk J; Chaber R; Gil L; Styczyński J
Mycoses; 2019 Nov; 62(11):990-998. PubMed ID: 31429997
[TBL] [Abstract][Full Text] [Related]
19. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
20. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Sun Y; Hu J; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Transpl Infect Dis; 2021 Aug; 23(4):e13611. PubMed ID: 33825274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
